


#### Current and Past Research on ME/CFS

# Maureen Hanson, Ph.D. Department of Molecular Biology and Genetics

## Center for Enervating NeuroImmune Disease



#### Predominant symptoms of ME/CFS



Created with BioRender

Institute of Medicine clinician's guide:

http://www.nationalacademies.org/hmd/Reports/2015/ME-CFS.aspx

# SF36 symptom survey indicates that ME/CFS patients have less quality of life than individuals with MS and Congestive Heart Failure

TABLE II

General health perceptions

Vitality

Social functioning

Role—emotional

Mental health

Mean

Mean

Mean

SD

P value\*

P value\*

P value\*

Mean

3D

SD

 $33.8 \pm$ 

 $25.7 \pm$ 

 $45.8 \pm$ 

 $62.9 \pm$ 

26.2

42.0

21.0

19.4

SF-36 Scales: Health Concepts		ČFŠ Boston (n = 223)	General Population Controls MOS (n = 2,474)	Hypertension MOS (n = 2,089)	Congestive Heart Failure MOS (n ~ 216)	Diabetes Type II MOS (n - 163)	AMI MOS (n = 107)	Depression MOS (n = 502)	Multiple Sclerosis Boston (n = 25)
Physical functioning	Mean SD P value*	54.5 ± 25.9	84.2 ± 23.3 <0.00001	73.4 ± 26.4 < 0.00001	47.5 ± 31.0 =0.00004	67.7 ± 28.7 <0.00001	69.7 ± 26.1 <0.00001	71.6 ± 27.2 <0.00001	53.2 ± 24.4 =0.4009
Role—physical	Mean SD P value*	17.1 ± 30.7	81.0 ± 34.0 <0.00001	62.0 ± 39.4 <0.00001	34.4 ± 39.7 <0.00001	56.8 ± 41.7 <0.00001	51.4 ± 39.4 <0.00001	44.4 ± 40.3 <0.00001	33.0 ± 41.3 <0.00001
Bodily pain	Mean SD P value*	49.7 ± 25.4	75.2 ± 23.7 <0.00001	72.3 ± 24.4 <0.00001	62.7 ± 31.0 <0.00001	68.5 ± 26.5 <0.00001	72.8 ± 25.2 < 0.00001	58.8 ± 26.7 <0.00001	70.9 ± 24.4 <0.00001

47.0 ±

 $44.3 \pm$ 

 $71.3 \pm$ 

 $63.7 \pm$ 

-0.3918

< 0.00001

74.7 ±

21.3

43.0

33.1

24.4

< 0.00001

< 0.00001

< 0.00001

24.2

63.3 ±

 $58.3 \pm$ 

86.7 ±

 $76.7 \pm$ 

77.9 ±

17.4

35.7

20.7

21.4

< 0.00001

< 0.00001

< 0.00001

< 0.00001

< 0.00001

19.7

 $72.0 \pm$ 

 $60.9 \pm$ 

83.3 ±

81.3 ±

74.7 ±

18.0

33.0

22.7

21.0

< 0.00001

< 0.00001

< 0.00001

< 0.00001

< 0.00001

20.3

Study performed by Anthony Komaroff at Harvard Medical School (chief editor of the Harvard Health Publications) "ask Doctor K"

 $56.1 \pm$ 

 $55.7 \pm$ 

 $82.0 \pm$ 

75.6 ±

76.7 ±

18.3

36.6

25.0

21.6

< 0.00001

< 0.00001

< 0.00001

< 0.00001

< 0.00001

21.1

52.9 ±

< 0.00001

< 0.00001

£00000.0>

< 0.00001

< 0.00001

23.0

40.1 ±

57.2 ±

 $38.9 \pm$ 

46.3 ±

20.8

27.7

39.8

21.1

44.8 ±

 $27.0 \pm$ 

 $60.5 \pm$ 

66.6 ±

=0.1077

66.9 ±

=0.0005

21.7

26.1

44.1

17.7

< 0.00001

=0.1369

<0.000001

18.1

59.2 ±

57.7 ±

19.0

81.6 ±

 $73.5 \pm$ 

 $75.8 \pm$ 

15.7

35.0

21.2

< 0.00001

< 0.00001

< 0.000001

=0.00002

< 0.00001

19.3

AL Komaroff et al. Am J Med. 1996 101:281-90.

#### Documented biological abnormalities in ME/CFS

Altered gut microbiome

Altered response to exercise by cardiopulmonary exercise testing

Altered levels of metabolites

Reduced natural killer cell function

Altered levels of inflammatory proteins, including cytokines

Changes in levels of molecules in the brain indicating increased oxidative stress or neuroinflammation

Differences in gene expression in immune cells

## Conclusions from Gut Bacterial Microbiome study

Less bacterial diversity present in patients compared to healthy population

Anti-inflammatory bacterial species are reduced in ME/CFS patients

83% of the samples could be correctly classified as ME/CFS or healthy using microbiome data and blood assays

Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome



#### Abnormalities in Leukocyte Function in ME/CFS

Clinical and Experimental Immunology

ORIGINAL ARTICLE

doi:10.1111/j.1365-2249.2005.02935.x

## Chronic fatigue syndrome is associated with diminished intracellular perforin

K. J. Maher,\* N. G. Klimas\*† and M. A. Fletcher\*

\*Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA, and

†Department of Medicine, Veterans Administration

Medical Center, Miami, FL, USA



B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment

Øystein Fluge<sup>1</sup>\*, Kristin Risa<sup>1</sup>, Sigrid Lunde<sup>1</sup>, Kine Alme<sup>1</sup>, Ingrid Gurvin Rekeland<sup>1</sup>, Dipak Sapkota<sup>1,2</sup>, Einar Kleboe Kristoffersen<sup>3,4</sup>, Kari Sørland<sup>1</sup>, Ove Bruland<sup>1,5</sup>, Olav Dahl<sup>1,4</sup>, Olav Mella<sup>1,4</sup>\*

Research

Plasma cytokines in women with chronic fatigue syndrome

Mary Ann Fletcher\*<sup>†1,2</sup>, Xiao Rong Zeng<sup>1,2</sup>, Zachary Barnes<sup>1</sup>, Silvina Levis<sup>1</sup> and Nancy G Klimas<sup>†1,2</sup>

OPEN & ACCESS Freely available online



## Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome

Madlen Loebel<sup>1</sup>\*\*, Kristin Strohschein<sup>1,2</sup>\*, Carolin Giannini<sup>1</sup>, Uwe Koelsch<sup>3</sup>, Sandra Bauer<sup>1</sup>, Cornelia Doebis<sup>4</sup>, Sybill Thomas<sup>1</sup>, Nadine Unterwalder<sup>3</sup>, Volker von Baehr<sup>4</sup>, Petra Reinke<sup>5,6</sup>, Michael Knops<sup>1</sup>, Leif G. Hanitsch<sup>1</sup>, Christian Meisel<sup>1,3</sup>, Hans-Dieter Volk<sup>1,5</sup>, Carmen Scheibenbogen<sup>1,5</sup>

Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients

Sharni Lee Hardcastle\*, Ekua Weba Brenu, Samantha Johnston, Thao Nguyen, Teilah Huth, Sandra Ramos, Donald Staines and Sonya Marshall-Gradisnik

#### Immunologic Abnormalities Associated with Chronic Fatigue Syndrome

Edward Barker, Sue F. Fujimura, Mitchell B. Fadem, Alan L. Landay, and Jay A. Levy From the Cancer Research Institute, Department of Medicine, University of California, San Francisco, California

#### BIOMARKERS

Distinct plasma immune signatures in ME/CFS are present early in the course of illness


Mady Hornig,<sup>1,2</sup>\* José G. Montoya,<sup>3</sup> Nancy G. Klimas,<sup>4</sup> Susan Levine,<sup>5</sup> Donna Felsenstein,<sup>6</sup> Lucinda Bateman,<sup>7</sup> Daniel L. Peterson,<sup>8</sup> C. Gunnar Gottschalk,<sup>8</sup> Andrew F. Schultz,<sup>1</sup> Xiaoyu Che,<sup>1</sup> Meredith L. Eddy,<sup>1</sup> Anthony L. Komaroff,<sup>9</sup> W. Ian Lipkin<sup>1,2,10</sup>

#### Research Article


A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis

Ekua W. Brenu, <sup>1</sup> Simon Broadley, <sup>2</sup> Thao Nguyen, <sup>1,3</sup> Samantha Johnston, <sup>1,3</sup> Sandra Ramos, <sup>1</sup> Don Staines, <sup>1</sup> and Sonya Marshall-Gradisnik <sup>1,3</sup>

#### Our group investigated function of two types of T cells




#### T cells use various types of energy sources to maintain themselves and to respond to activation signals



# The energetic functioning of T cells can be examined by measures of metabolic pathways and mitochondrial characteristics



Agilent Seahorse assays
to measure activity of:
Oxidative phosphorylation
Glycolysis
Fatty acid oxidation



Created with Biorender: Jessica Maya


#### Patient population for T cell study

Controls ME/CFS


45 53 Illness duration  $21.7 \pm 12$  yrs




Daniel Peterson, M.D.
Gunnar Gottschalk
Marco Maynard
Jineet Patel
Incline Village, Nevada



#### Dysfunction of CD4+ and CD8+ T Cells in ME/CFS





Alexandra H. Mandarano, <sup>1</sup> Jessica Maya, <sup>1</sup> Ludovic Giloteaux, <sup>1</sup> Daniel L. Peterson, <sup>2</sup> Marco Maynard, <sup>3</sup> C. Gunnar Gottschalk, <sup>3</sup> and Maureen R. Hanson <sup>1</sup>


More in:

Harvard OMF Symposium <a href="https://www.youtube.com/watch?time\_continue=1&v=QAdZN">h?time\_continue=1&v=QAdZN</a>
U6D7Gs

Videos from InvestinME Conference and the April NIH Conference at <a href="https://neuroimmune.cornell.ed/u/news/">https://neuroimmune.cornell.ed/u/news/</a>

*J Clin Invest.* 2020;<u>130(3)</u>:1491-1505.

Our current studies use samples before and after a provocation



The molecular basis of post-exertional malaise can be studied by induction of symptoms by two successive CPETs








In 94 patients tested at Ithaca College:

Physiologic dysfunction	34%
Anaerobic dysfunction	39%
Autonomic dysfunction	43%
Reproduced normally	29%




Betsy Keller, Ph.D.

# Plasma metabolite comparisons may reveal differences in functioning of tissues and organs




#### Plasma metabolites analyzed by Metabolon, Inc.

933 metabolites identified




# Exercise increases the number of metabolites significantly different between controls and patients



933 metabolites identified

## **Work in Progress**

Pathway Analysis



Integration of physiological measures and clinical information

#### **Graded Exercise Therapy**

No accepted evidence that such programs result in recovery from ME/CFS

An infamous study known as the PACE trial, carried out in the UK, claimed recovery due to flawed performance and analysis

Patients forced into such programs often report permanent harm

#### Recommendation made by ME/CFS expert physicians:

Balance activity and rest ("Pacing")

Avoid over-exertion, prevent induction of post-exertional malaise

Will usually require part-time work at most, or part-time school with physical education modification

#### Some ways to improve quality of life for ME/CFS patients

#### By treating symptoms with appropriate drugs:

Headaches (often migraines) Muscular pain and tightness Low blood volume Orthostatic intolerance Unrefreshing sleep

Recommending pacing to avoid post-exertional malaise

By not expressing disbelief in the physical nature of the illness

If psychological counseling seems advisable, explaining that it can help with coping with a chronic **physical** illness

By not recommending counterproductive "therapies" such as unmonitored aerobic exercise



#### **Center for Enervating NeuroImmune Disease**



Cornell University in Ithaca, NY

Weill Cornell Medicine in Manhattan, NY

The Cambridge Dictionary defines "Enervating" as: adjective

causing you to feel weak and lacking in energy

#### **About the Cornell ENID Center**

Foremost among cryptic neuroimmune diseases is one variously known as Myalgic Encephalomyelitis or Chronic Fatigue Syndrome or Systemic Exertion Intolerance Disease. The Center's mission is to promote research to identify its cause(s), biomarkers, and pathophysiology in order to lead to prevention and effective treatments.

#### Webinars available under News tab

#### Acknowledgments



The Hanson Lab Biomedical Group



Daniel Peterson Gunnar Gottschalk Marco Maynard Ivan Falstyn Jineet Patel

#### Cornell NIH Center

Betsy Keller Geoffrey Moore Susan Levine John Chia Staci Stevens Jared Stevens Dikoma Shungu Xiangling Mao Carl Franconi
Jessica Maya
Ludovic Giloteaux
Arnaud Germain
Adam O'Neal
Alex Mandarano
Ivan Falstyn
Madeline McCanne
Vivian Huang

Jesús Castro-Marrero

Metabolon, Inc.

Cornell proteomics: Sheng Zhang



Cornell University
Sloan Foundation
Private donors
Simmaron Research